Empagliflozin treatment effects across categories of baseline HbA1c , body weight and blood pressure as an add‐on to metformin in patients with type 2 diabetes
| Autor: | Isabella Zwiener, Naveed Sattar, Jyothis T. George, Prabhav Trivedi, Silvio E. Inzucchi, Kamlesh Khunti, Melanie J. Davies, Odd Erik Johansen |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty endocrine system diseases Endocrinology Diabetes and Metabolism empagliflozin Urology Blood Pressure 030209 endocrinology & metabolism Type 2 diabetes 030204 cardiovascular system & hematology Body weight Placebo 03 medical and health sciences 0302 clinical medicine Endocrinology Double-Blind Method Glucosides Internal Medicine medicine Empagliflozin Humans Hypoglycemic Agents In patient Benzhydryl Compounds Adverse effect Aged Glycated Hemoglobin business.industry Body Weight SGLT2 inhibitor Original Articles Middle Aged medicine.disease Metformin Treatment Outcome glycaemic control Blood pressure Diabetes Mellitus Type 2 Drug Therapy Combination Female Original Article type 2 diabetes business medicine.drug |
| Zdroj: | Diabetes, Obesity & Metabolism |
| ISSN: | 1463-1326 1462-8902 |
| DOI: | 10.1111/dom.14234 |
| Popis: | Aim To investigate the association of different categories of baseline cardio‐metabolic risk factors on the treatment effects of empagliflozin 10 and 25 mg when added as second‐line therapy to metformin in patients with type 2 diabetes (T2D). Materials and Methods Patients aged 18 years or older with HbA1c 7.0%‐10.0% were included. Analysis of covariance compared change from baseline to weeks 24 and 76 in HbA1c, body weight (BW) and systolic blood pressure (SBP) by respective baseline categories (HbA1c 90 kg, SBP 140 mmHg). Analyses were also conducted with a model using continuous covariates of cardio‐metabolic factors. Results In total, 637 patients (56.7% males; mean [SD] age 55.7 [9.9] years, HbA1c 7.9% [0.9%], BW 81.2 [18.8] kg, SBP 129.4 [14.6] mmHg) received one or more dose of either empagliflozin 10 mg (n = 217) or 25 mg (n = 213), or placebo (n = 207). At both time points, empagliflozin 10/25 mg versus placebo significantly (P < .0001) reduced HbA1c and BW, with greater reductions in HbA1c at higher baseline HbA1c (P interaction week 24/76 categorical and continuous models: .0290/.1431 and .0004/.0042, respectively) and in BW (P interaction .1340/.0012 and .0202/ |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text